zemin wan

Mr. zemin wan

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2016 in International Immunopharmacology
Verified
Journal Article
Closed access
ZWzemin wan
zemin wan
XZXiujuan Zhang
Xiujuan Zhang
APAnping Peng
Anping Peng
MHMin He
Min He
ZLZhenhua Lei
Zhenhua Lei
YWYunxiu Wang
Yunxiu Wang

26 December 2021 in Journal of Clinical Laboratory Analysis
Verified
Journal Article
Open access
PDF file
LHLina He
Lina He
JYJinqi Yu
Jinqi Yu
GHGuang Han
Guang Han
DHDi Huang
Di Huang
LHLiqiao Han
Liqiao Han
XWXiaobin Wu
Xiaobin Wu
Background: Serum creatinine (SCr) is a useful diagnostic marker for the assessment of renal function. Accurate quantitation of SCr is clinically important in calculation of glomerular filtration rate (GFR).Method: To confirm whether there are differences in SCr between enzymatic kits of different manufacturers, the analytical performance of the matched and open test system in the measurement of SCr was evaluated. The analytical performance evaluation was conducted according to the Clinical and Laboratory Standards Institute (CLSI) guidelines. Precision, accuracy, linearity, dilution, lower limit of measurement and analytical interference were studied between the two test systems.Results: The performance of SCr from the open test system was in compliance with the matched test system with good precision, accuracy, and linearity. In presence of most common interferents, both test systems could lead to accurate creatinine results except for the existence of specified drugs. For dobutamine, the open test system showed better anti‐interference performance than the matched system.Conclusion: This study provides referable opinions for clinical laboratory selection on the test system and a framework for future analogous studies based on different test systems.

7 August 2025 in Biology
Verified
Journal Article
Open access
PDF file
LHLu Huang
Lu Huang
YDYing Dong
Ying Dong
JLJinhang Li
Jinhang Li
XYXinyu Yang
Xinyu Yang
XLXiaoqiong Li
Xiaoqiong Li
PZPengwei Zhang
Pengwei Zhang
The epidermal growth factor receptor (EGFR) is a key target for both cancer diagnosis and therapeutic interventions. Assessing EGFR expression before therapy has become routine in clinical practice, yet current methods like biopsy and immunohistochemistry (IHC) have significant limitations, including invasiveness, limited repeatability, and lack of real-time, whole-body data. EGFR-targeted imaging has emerged as a promising alternative. EGFR-targeting peptides, owing to their favorable physicochemical properties and versatility, are increasingly being explored for a variety of applications, including molecular imaging, drug delivery, and targeted therapy. Recent advances have demonstrated the potential of EGFR-targeting peptides conjugated to imaging probes for non-invasive, real-time in vivo tumor detection, precision therapy, and surgical guidance. Here, we provide a comprehensive overview of the latest progress in EGFR-targeting peptides development, with a particular focus on their application in the development of molecular imaging agents, including fluorescence imaging, PET/CT, magnetic resonance imaging, and multimodal imaging. Furthermore, we examine the challenges and future directions concerning the development and clinical application of EGFR-targeting peptide-based imaging probes. Finally, we highlight emerging technologies such as artificial intelligence, mutation-specific peptides, and multimodal imaging platforms, which offer significant potential for advancing the diagnosis and treatment of EGFR-targeted cancers.

6 June 2022 in Frontiers in Pharmacology
Verified
Journal Article
Open access
XDXiaoming Dong
Xiaoming Dong
XHXiaowei Han
Xiaowei Han
XZXiaojiao Zhang
Xiaojiao Zhang
SLSijing Li
Sijing Li
ZLZiru Li
Ziru Li
ZWzemin wan
zemin wan
Nuanxinkang tablet (NXK), a Chinese herbal formula, can improve heart function and quality of life in patients with chronic heart failure (CHF). However, the mechanisms of action of NXK are not fully understood. In this study, we investigated the effects of NXK on inflammation in the CHF mouse model. This model was established by transverse aortic constriction (TAC) and treated with NXK for 8 weeks. Then, the cardiac function and myocardial fibrosis were evaluated. The monocytes/macrophages were evaluated by immunofluorescence. The mRNA levels of IL-1β, IL-6, TNF-α, ICAM-1, and VCAM-1 were measured by quantitative real-time polymerase chain reaction (qRT-PCR), while TLR4, MyD88, NF-κB p65, P-IκBα, TLR2, TLR7 and TLR9 protein levels were evaluated by Western blot. The results showed that NXK improved the left ventricular ejection fraction (LVEF) and left ventricular end-systolic dimension, reversed myocardial fibrosis, and inhibited pro-inflammatory (CD11b + Ly6C+) monocytes/macrophages in the TAC mouse model. NXK also reduced the mRNA and protein levels of the above markers. Taken together, NXK improved heart function and reduced inflammation through the TLR-mediated NF-κB signaling pathway, suggesting that it might be used as an innovative treatment strategy for CHF.

1 March 2022 in Journal of Laboratory Medicine
Verified
Journal Article
Open access
PDF file
YWYunxiu Wang
Yunxiu Wang
BWBaiye Wang
Baiye Wang
LSLanhui She
Lanhui She
JWJijuan Wang
Jijuan Wang
YCYingting Chen
Yingting Chen
HLHongcan Liu
Hongcan Liu
Objectives: To investigate the influence of preservation methods and processes on the plasma interleukin-6 (IL-6) stability. Methods: Lithium-heparin plasma was collected from female patients: 32 female patients with invasive breast neoplasms and 20 healthy females. Each sample was divided into three tubes. Samples were stored at different temperatures or at different times. The concentration of IL-6 was detected. Results: IL-6 levels in patients were not altered significantly compared to the control group after storage at 4 °C or 25 °C for 12 h. However, IL-6 levels were significantly higher compared to controls (p<0.05) after storage at 25 °C for 48 h. IL-6 levels in patients with breast neoplasms were significantly higher compared to the control group (p<0.05) when stored at 4 °C after 12 h. IL-6 levels in patients with breast neoplasm increased more than 10-folds compared to the control group after only 2 h storage at 25 °C. Conclusions: Concentrations of IL-6 in breast neoplasms samples significantly change under different storage conditions. Pretreatment needs to be standardized for blood sample handling procedure. Comparison of different storage conditions of IL-6 levels may not be reliable.

1 January 2018 in Clinical Laboratory
Verified
Journal Article
Closed access
YCYan Chao
Yan Chao
ZWzemin wan
zemin wan
XWXiaobin Wu
Xiaobin Wu
FQFeng Qiu
Feng Qiu
YWYunxiu Wang
Yunxiu Wang
XHXianzhang Huang
Xianzhang Huang
The presence of hemoglobinopathies could interfere with some assays for Hemoglobin A1c (HbA1c) measurement; therefore, the effect of thalassemia on ion-exchange high-performance liquid chromatography (IEHPLC) method Tosoh HLC-723 G8 (Tosoh G8) was evaluated. A total of 43 normal controls and 101 thalassemia patients were quantified by Premier Hb9210 and Tosoh G8 (variant-mode) systems. At the same time, 7 normal controls and 8 thalassemia patients were confirmed by the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) reference method for verification. For normal controls, the HbA1c values of Tosoh G8 system (y) showed great correlation and agreement with those from Premier Hb9210 (x) (y = 0.9688x + 0.2151, r = 0.9951; mean difference 0.02 ± 0.30%), and no significant relative bias above 7% was observed; the HbA1c values obtained by Tosoh G8 were consistent with the IFCC targets (relative bias < ± 6%) in all of the samples. However, for thalassemia, the correlation between Tosoh G8 (y) and Premier Hb9210 (x) became relatively low (y = 0.8079x + 1.2897, r = 0.7780); the HbA1c values of 91.1% of the samples (92/101) obtained by Tosoh G8 were higher than those by Premier Hb9210 (mean difference 0.33 ± 0.48%) and a significant positive bias above 7% was noticed in 43.3% (45/101) thalassemia patients; when compared with the IFCC targets, the 87.5% (7/8) relative bias was > ± 6%. Thalassemia could directly affect the measurement of HbA1c using the IE-HPLC method Tosoh G8 and the clinical laboratorial staff should pay close attention.